Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Activity of DPP-IV inhibitor GRC-8087 characterized in vitro, in vivo

Sep. 8, 2004

ISF-402 mechanism of action explored in vivo

Sep. 8, 2004

R-483 reduces insulin, triglycerides in type 2 diabetes model

Sep. 8, 2004

Studies reveal preclinical activity and tolerability of SOM-230

Sep. 8, 2004

JTZ-132 induces megakaryopoiesis in CD34+ cells

Sep. 8, 2004

Liraglutide increases the effects of metformin on glycemic control of diabetic patients

Sep. 8, 2004

Novel PPARalpha/PPARgamma agonists discovered at Merck KGaA

Sep. 8, 2004

Oral ibandronate found to reduce fracture risk in postmenopausal osteoporosis

Sep. 8, 2004

Good safety and pharmacokinetic profile of tanaproget in healthy women

Sep. 7, 2004

An interim analysis provides new evidence of the efficacy of CJC-1131 in type 2 diabetes

Sep. 7, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...